Correlation Between GRI Bio and Zenas BioPharma,

Can any of the company-specific risk be diversified away by investing in both GRI Bio and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GRI Bio and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between GRI Bio and Zenas BioPharma, Common, you can compare the effects of market volatilities on GRI Bio and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GRI Bio with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of GRI Bio and Zenas BioPharma,.

Diversification Opportunities for GRI Bio and Zenas BioPharma,

0.56

Correlation Coefficient

GRI Bio  Zenas BioPharma,

Very weak diversification

The 3 months correlation between GRI and Zenas is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding GRI Bio and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and GRI Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on GRI Bio are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of GRI Bio i.e., GRI Bio and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between GRI Bio and Zenas BioPharma,

Considering the 90-day investment horizon GRI Bio is expected to under-perform the Zenas BioPharma,. In addition to that, GRI Bio is 1.01 times more volatile than Zenas BioPharma, Common. It trades about -0.14 of its total potential returns per unit of risk. Zenas BioPharma, Common is currently generating about 0.01 per unit of volatility. If you would invest  1,005  in Zenas BioPharma, Common on December 26, 2024 and sell it today you would lose (94.00) from holding Zenas BioPharma, Common or give up 9.35% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

GRI Bio  vs.  Zenas BioPharma, Common

GRI Bio

Risk-Adjusted Performance

Very Weak

Over the last 90 days GRI Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Etf's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The recent confusion may also be a sign of long-lasting up-swing for the Etf traders.

Zenas BioPharma, Common

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Zenas BioPharma, is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with GRI Bio and Zenas BioPharma,

The main advantage of trading using opposite GRI Bio and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GRI Bio position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.

The idea behind GRI Bio and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.